In a filing, Verve Therapeutics Inc revealed its insider Ashe Andrew D. acquired Company’s shares for reported $0.48 million on May 14 ’24. In the deal valued at $6.26 per share,76,000 shares were bought. As a result of this transaction, Ashe Andrew D. now holds 342,509 shares worth roughly $2.16 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Nickerson Joan sold 1,514 shares, generating $12,475 in total proceeds. Upon selling the shares at $8.24, the Chief Administrative Officer now owns 8,659 shares.
Before that, Dorval Allison sold 554 shares. Verve Therapeutics Inc shares valued at $6,343 were divested by the Chief Financial Officer at a price of $11.45 per share. As a result of the transaction, Dorval Allison now holds 4,060 shares, worth roughly $25618.6.
H.C. Wainwright initiated its Verve Therapeutics Inc [VERV] rating to a Buy in a research note published on April 08, 2024; the price target was $15. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in mid April with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering VERV with “Neutral” recommendation on February 01, 2023. Goldman started covering the stock on December 15, 2022. It rated VERV as “a Sell”.
Price Performance Review of VERV
On Friday, Verve Therapeutics Inc [NASDAQ:VERV] saw its stock fall -0.79% to $6.31. Over the last five days, the stock has gained 6.41%. Verve Therapeutics Inc shares have fallen nearly -54.73% since the year began. Nevertheless, the stocks have fallen -62.33% over the past one year. While a 52-week high of $19.34 was reached on 02/29/24, a 52-week low of $4.30 was recorded on 08/14/24. SMA at 50 days reached $5.48, while 200 days put it at $7.59.
Levels Of Support And Resistance For VERV Stock
The 24-hour chart illustrates a support level at 6.18, which if violated will result in even more drops to 6.04. On the upside, there is a resistance level at 6.42. A further resistance level may holdings at 6.52. The Relative Strength Index (RSI) on the 14-day chart is 65.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.11%. Stochastics %K at 70.20% indicates the stock is a holding.
How much short interest is there in Verve Therapeutics Inc?
A steep rise in short interest was recorded in Verve Therapeutics Inc stocks on 2024-10-15, growing by 1.57 million shares to a total of 17.44 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 15.87 million shares. There was a rise of 9.01%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 06, 2022 when Credit Suisse began covering the stock and recommended ‘”a Neutral”‘ rating along with a $48 price target.
